NCT07359820
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07359820
Title A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement (ReFocus202)
Acronym ReFocus202
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Elevar Therapeutics
Indications
Therapies
Age Groups: senior
Covered Countries USA | GBR | FRA | ESP

Facility Status City State Zip Country Details
Mayo Clinic Phoenix Arizona 85054 United States Details
Mayo Clinic Jacksonville Florida 32224 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
University of Chicago Medical Center Chicago Illinois 60637 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10022 United States Details
The University of Texas M.D. Anderson Cancer Center Houston Texas 77030 United States Details
Institut Bergonie Bordeaux 33076 France Details
Centre Georges François Leclerc Dijon 21079 France Details
Centre Leon Berard Lyon 69373 France Details
Gustave Roussy Cancer Campus Paris 94805 France Details
Seoul National University Hospital Seoul 03080 South Korea Details
Samsung Medical Center Seoul 06351 South Korea Details
START Barcelona-Hospital HM Nou Delfos Barcelona 08023 Spain Details
Hospital Universitario Fundación Jiménez Díaz- START MADRID Madrid 28040 Spain Details
Hospital Universitario HM Sanchinarro-START MADRID-CIOCC Madrid 28050 Spain Details
Sarah Cannon Research Institute UK London W1G 6AD United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field